𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)

✍ Scribed by Imashuku, Shinsaku ;Morimoto, Akira ;Kuriyama, Kikuko ;Kano, Gen ;Hibi, Shigeyoshi ;Todo, Shinjiro

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
46 KB
Volume
41
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of imatinib in patie
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-Ξ±
✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 201 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not

Significance of suboptimal response to i
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 338 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during